Europe
Molecular Partners announced yesterday it has filed for a $100 million initial public offering with the Securities and Exchange Commission in the U.S., funding which will go toward supporting the company’s work in the development of protein-based treatments for COVID-19 and various cancers.
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.
The same group at the University of Oxford and the Jenner Institute that developed the AstraZeneca-Oxford COVID-19 vaccine reported that their investigational malaria vaccine, R21/Matrix-M, demonstrated 77% efficacy in children over 12 months of follow-up.
The approval was specifically for patients with recurrent or advanced endometrial cancer who had progressed on or after previous treatment with platinum-based chemotherapy and whose cancers have a dMMR genetic anomaly.
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them.
The Swiss pharma giant quietly announced the cuts this morning in a breakdown of its first quarterly financial report.
Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.
PRESS RELEASES